44.04

0.02% 0.010

First Tracks Biotherapeutics Inc (TRAX)

Overview News Price History Discussions Forecast

First Tracks Biotherapeutics Inc stock is traded at $44.04, with a volume of 446.15K. It is up +0.02% in the last 24 hours and up +28.14% over the past month. First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Previous Close:

$44.03

Open:

$43.46

24h Volume:

446.15K

Relative Volume:

0.62

Market Cap:

$1.54B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-2.85%

1M Performance:

+28.14%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$42.41

$45.35

1-Week Range:

$42.41

$49.91

52-Week Range:

$14.72

$49.91

First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile

Name

First Tracks Biotherapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

212-373-3000

Address

10770 WATERIDGE CIRCLE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

TRAX's Discussions on Twitter

Compare TRAX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRAX First Tracks Biotherapeutics Inc	44.04	1.61B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Initiated	Leerink Partners	Outperform
Apr-24-26	Initiated	Wedbush	Outperform
Apr-23-26	Initiated	JP Morgan	Overweight
Apr-22-26	Initiated	Barclays	Overweight
Apr-21-26	Initiated	UBS	Buy

First Tracks Biotherapeutics Inc Stock (TRAX) Latest News

Aug 13, 2026

First Tracks Biotherapeutics (NASDAQ: TRAX) Share Price, TRAX Stock News, TRAX Share Price & Updates - kalkine.ca

Aug 13, 2026

First Tracks Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $63.38, Implies 37% Upside - TradingView

Aug 13, 2026

Piper Sandler raises First Tracks stock price target on pipeline progress - Investing.com Australia

Aug 13, 2026

TRAX Maintained by First Tracks -- Price Target Raised to $95.00 - GuruFocus

Aug 13, 2026

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results - benzinga.com

Aug 13, 2026

TRAX Maintained by HC Wainwright & Co. -- Price Target Raised to $57.00 - GuruFocus

Aug 13, 2026

Wedbush Adjusts PT on First Tracks Biotherapeutics to $70 From $60, Maintains Outperform Rating - marketscreener.com

Aug 13, 2026

First Tracks Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $60.5, Implies 31% Upside - tradingview.com

Aug 13, 2026

TRAX SWOT Analysis: Clinical Pipeline and Financial Challenges R - GuruFocus

Aug 13, 2026

Aug 12, 2026

Form 8K FIRST TRACKS BIOTHERAPEUTICS For: 12 August By Investing.com - Investing.com South Africa

Aug 12, 2026

First Tracks Biotherapeutics 2Q 2026: Net loss $(33.4M), EPS $(0.95) — 10-Q Summary - TradingView

Aug 12, 2026

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times

Aug 12, 2026

First Tracks Biotherapeutics (TRAX) details $83.9M loss and $168M cash after spin-off - Stock Titan

Aug 12, 2026

CBRS Stock Quote Price and Forecast - CNN

Aug 12, 2026

First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com

Aug 12, 2026

Aug 11, 2026

FMR LLC Acquires Stake in First Tracks Biotherapeutics Inc (TRAX): A Strategic Bet on Clinical-Stage Innovation - GuruFocus

Aug 11, 2026

Aug 10, 2026

UBS Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $65 - Moomoo

Aug 10, 2026

UBS Adjusts First Tracks Biotherapeutics PT to $65 From $45, Maintains Buy Rating - Moomoo

Aug 10, 2026

Aug 07, 2026

First Tracks Biotherapeutics (TRAX) reports 16,667 performance stock units - Stock Titan

Aug 07, 2026

AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? - Investing.com

Aug 07, 2026

AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com - Investing.com Canada

Aug 07, 2026

Aug 05, 2026

First Tracks Biotherapeutics (TRAX) awards 60,492 performance stock units - Stock Titan

Aug 05, 2026

First Tracks Biotherapeutics (TRAX) awards 60,492 PSUs to CMO - Stock Titan

Aug 05, 2026

Jul 31, 2026

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR - RTTNews

Jul 31, 2026

Jul 29, 2026